Modeling human osteosarcoma in the mouse: From bedside to bench
Katherine A Janeway, Carl R Walkley
Bone | ELSEVIER SCIENCE INC | Published : 2010
Osteosarcoma (OS) is the most common primary tumour of bone, occurring predominantly in the second decade of life. High-dose cytotoxic chemotherapy and surgical resection have improved prognosis, with long-term survival for patients with localized (non-metastatic) disease approaching 70%. At presentation approximately 20% of patients have metastases and almost all patients with recurrent OS have metastatic disease and cure rates for patients with metastatic or recurrent disease remain poor (<20% survival). Over the past 20 years, considerable progress has been made in the understanding of OS pathogenesis, yet these insights have not translated into substantial therapeutic advances and clinic..View full abstract
We thank Dr Tony Mutsaers for critical reading and comment Work in C.R.W's laboratory is supported by grants from the NHMRC of Australia. C.R.W. was a Special Fellow of the Leukemia & Lymphoma Society, an NHMRC Career Development Award holder and is the Leukaemia Foundation Phillip Desbrow Senior Research Fellow.